Speakers Cory and Libby will discuss the latest in DEA law and policy impacting the supply chain and patients. During the pandemic, DEA rules for online prescribing of controlled substances were waived, which increased patient access to care for conditions often treated with controlled substances, including substance use disorder (SUD) and attention deficit hyperactivity disorder (ADHD). Post-pandemic, DEA has been working on a slew of new rules to keep pace with changes in distribution and dispensing. This panel will explore these DEA developments. Speakers will download on the new/anticipated DEA rules on the Ryan Haight Act expected in the spring 2024 – including telehealth prescribing and related red flag dispensing issues. They will also discuss updates related to Suspicious Orders, the impact of controlled substance shortages, and patient risk of getting counterfeits from grey market online sellers.
Learning Objectives:
Upon completion, participant will be able to learn the latest regulatory action with the Ryan Haight Act and controlled substance prescribing through telehealth.
Upon completion, participant will be able to understand the DEA geographic restrictions “red flag” and its implications on patients receiving their medications.
Upon completion, participant will be able to understand the latest in Suspicious Orders rules and risks
Upon completion, participant will be able to hear about what patients do when the controlled substances they are prescribed are inaccessible.
